Our cervical cytology machine learning algorithm looks for precancerous and cancerous cells as well as other diagnostically important organisms in pap smears. Our software then presents suspicious images to the cytotech for review.
Cervical Cancer Screening
Challenge & Solution
Using current methods, a cytotech is expected to use a microscope to review, on average, 40,000 to 50,000 cells per slide. In contrast, our software presents the 200 most clinically relevant images to the cytotech for review. This review process is completed on a computer monitor rather than a microscope.
Our software can help laboratories perform cervical cytology tests with increased accuracy and efficiency while also reducing costs.
A recent hospital study yielded the following results:
How it works
Our Cervical Cytology (PAP) software screens and evaluates SurePath and ThinPrep slides, scanned on the Hamamatsu, 3DHistech, or Motic Scanners.
The results are then presented to a trained cytotech for review. When an atypical cell is identified, the slide is manually reviewed using a microscope.
At this time, due to their unpredictable nature, conventional manually-prepared pap smears are not supported. The Techcyte Cervical Cytology (Papanicolaou) Test is not yet FDA approved for clinical use and is to be used as a lab-developed test to assist pathologists in their diagnosis.
- Trichomonas Vaginalis
- Clue Cells
- Actinomyces Spp.
- Herpes Simplex
- Atypical Glandular – NOS
- Typical Endocervical Cell
- Atypical Glandular – Favor Neoplastic
- Endocervical Adenocarcinoma In Situ
- Adenocarcinoma (endocervical, endometrial, extrauterine, NOS)
- Neutrophil Cell
Our algorithm increases accuracy and efficiency when confirming proposed atypical cells. Additionally, we directly address the growing shortage of qualified cytotechs by offering a remote working environment, and make this historically negative contribution margin test profitable.